Loading
CAR-T Cell Therapy Research / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
Journal of Clinical Medicine · August 18, 2026
A consensus or society position rather than new primary data.
This narrative review consolidates current knowledge on cardiovascular toxicities associated with CAR-T cell therapy and bispecific T-cell engagers, ranging from hemodynamic perturbations to severe events such as malignant arrhythmias and cardiogenic shock. The review identifies that these toxicities operate via distinct pathophysiological mechanisms—some linked to cytokine release syndrome, others independent—and proposes management frameworks including baseline risk stratification, cardiac biomarker monitoring, and tocilizumab-based immunosuppression. Critical evidence gaps remain, including poorly characterized long-term cardiovascular outcomes, lack of validated surveillance protocols, and underrepresentation of cardiovascular endpoints in pivotal trials.
Narrative review. Patients with relapsed and refractory hematologic malignancies treated with CAR-T cells or bispecific T-cell engagers.
CAR-T cells and bispecific T-cell engagers achieve unprecedented response rates in relapsed and refractory hematologic malignancies Cardiovascular toxicities range from common hemodynamic perturbations (hypotension, tachycardia) to severe events including malignant arrhythmias, left ventricular dysfunction, myocardial infarction, and cardiogenic shock Toxicity frequency and pattern differ between CAR-T and bispecific T-cell engagers
No quantitative data on incidence, prevalence, or severity of specific cardiovascular toxicities provided Cardiovascular toxicities range from common hemodynamic perturbations (hypotension, tachycardia) to severe events including malignant arrhythmias, left ventricular dysfunction, myocardial infarction, and cardiogenic shock
Clinicians managing patients on CAR-T or bispecific T-cell engager therapies should implement proactive cardiovascular risk stratification, serial cardiac biomarker monitoring, and consider tocilizumab for cytokine release syndrome mitigation. Given evidence gaps in long-term outcomes and lack of standardized surveillance protocols, multidisciplinary cardio-oncology collaboration is warranted, and cardiovascular endpoints should be prioritized in pivotal trial design.
A narrative review synthesizing pathophysiology, clinical spectrum, and management of cardiovascular toxicities in CAR-T and bispecific T-cell engagers, proposing clinical algorithms and multidisciplinary frameworks for an emerging cardio-oncology area.
As stated by the source record.
Clinicians managing patients on CAR-T or bispecific T-cell engager therapies should implement proactive cardiovascular risk stratification, serial cardiac biomarker monitoring, and consider tocilizumab for cytokine release syndrome mitigation. Given evidence gaps in long-term outcomes and lack of standardized surveillance protocols, multidisciplinary cardio-oncology collaboration is warranted, and cardiovascular endpoints should be prioritized in pivotal trial design.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Chimeric antigen receptor T-cell therapy and bispecific T-cell engagers have transformed treatment of relapsed and refractory hematologic malignancies, achieving unprecedented response rates. However, their clinical adoption has revealed a complex spectrum of cardiovascular toxicities, differing in frequency and pattern between the two technologies. Manifestations range from common hemodynamic perturbations—hypotension and tachycardia—to severe events, including malignant arrhythmias, left ventricular dysfunction, myocardial infarction, and cardiogenic shock. These complications seem to have different pathophysiological pathways that are yet to be completely understood: on the one hand, they are frequently intertwined with cytokine release syndrome, the hallmark immune complication of T-cell-redirecting therapies, as seen with chimeric antigen receptor T-cell therapy; on the other, a substantial proportion of cardiovascular events—particularly with bispecific T-cell engagers—occur independently of cytokine release syndrome. Proposed cardiotoxic mechanisms include on-target, off-tumor antigen recognition and consequent damage; interleukin-6-driven systemic inflammation; and off-target, off-tumor antigen cross-reactivity. Effective management requires proactive baseline risk stratification, serial cardiac biomarker monitoring, and timely immunosuppressive intervention—primarily tocilizumab—to mitigate cytokine release syndrome-driven injury. Despite rapid clinical expansion, critical gaps remain: long-term cardiovascular outcomes are poorly characterized, validated surveillance protocols are lacking, and cardiovascular endpoints are rarely included in pivotal trials. This narrative review appraises the pathophysiology, clinical spectrum, and management of cardiovascular toxicities associated with these therapies, aiming to define this emerging cardio-oncology frontier, inform multidisciplinary care frameworks and propose a clinical management algorithm.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.